Mon, September 10, 2018
Fri, September 7, 2018
Thu, September 6, 2018
Wed, September 5, 2018
Tue, September 4, 2018

Alethia Young Initiated (SRPT) at Buy and Held Target at $178 on, Sep 6th, 2018

Alethia Young of Credit Suisse, Initiated "Sarepta Therapeutics, Inc." (SRPT) at Buy and Held Target at $178 on, Sep 6th, 2018.

Alethia has made no other calls on SRPT in the last 4 months.



There are 7 other peers that have a rating on SRPT. Out of the 7 peers that are also analyzing SRPT, 0 agree with Alethia's Rating of Hold.



These are the ratings of the 7 analyists that currently disagree with Alethia


  • Matthew Harrison of "Morgan Stanley" Upgraded from Hold to Buy on, Wednesday, August 1st, 2018
  • Brian Skorney of "Baird" Maintained at Buy with Increased Target to $202 on, Thursday, June 21st, 2018
  • Christopher Marai of "Nomura" Maintained at Strong Buy with Increased Target to $205 on, Thursday, June 21st, 2018
  • Joseph Schwartz of "Leerink Swann" Maintained at Buy with Increased Target to $196 on, Wednesday, June 20th, 2018
  • Debjit Chattopadhyay of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $267 on, Tuesday, June 19th, 2018
  • Yun Zhong of "BTIG" Initiated at Strong Buy and Held Target at $120 on, Friday, June 15th, 2018
  • Gena Wang of "Barclays" Upgraded from Hold to Buy on, Friday, May 11th, 2018